Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07464951 · ClinicalTrials.gov registry record · Phase 1
CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia
A Phase 1 study, sponsored by Stephan Grupp MD PhD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT07464951 is a Phase 1 study that is actively recruiting participants, run by Stephan Grupp MD PhD. The registered enrollment target is 30 participants.
The verdict
NCT07464951, a Phase 1 study, is actively recruiting participants, sponsored by Stephan Grupp MD PhD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study is designed to evaluate the safety and effectiveness of CART123 cells either alone or when combined with ruxolitinib in pediatric and young adult subjects with relapsed or refractory AML. Subjects will be enrolled into one of two treatment cohorts: subjects who will receive CART123 alone (Cohort A) or subjects who will receive CART123 in combination with ruxolitinib (Cohort B).
Interventions
- BIOLOGICAL Anti-CD123 LV redirected T cells (CART123)
- DRUG Ruxolitinib (JAKAVI®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-05-14 |
| Est. Completion | 2030-05-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07464951
The ClinicalTrials.gov registry entry for NCT07464951 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stephan Grupp MD PhD, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Anti-CD123 LV redirected T cells (CART123) is the first listed.
NCT07464951 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07464951 about?
NCT07464951 is a clinical study titled "CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia". This study is designed to evaluate the safety and effectiveness of CART123 cells either alone or when combined with ruxolitinib in pediatric and young adult subjects with relapsed or refractory AML. Subjects will be enrolled into one of two treatment cohorts: subjects who will receive CART123 alone ...
What is the current status of trial NCT07464951?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2026-05-14. Estimated completion is 2030-05-14.
What interventions are being tested in trial NCT07464951?
The interventions under investigation include: Anti-CD123 LV redirected T cells (CART123) (BIOLOGICAL), Ruxolitinib (JAKAVI®) (DRUG).
Who is sponsoring clinical trial NCT07464951?
This trial is sponsored by Stephan Grupp MD PhD, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.